Re:Gut Bacteria from Amphibians and Reptiles Achieve Complet...
by estearum on Thursday December 18, 2025 @09:58AM
(#46313350)
Agreed it isn't necessarily a bad reason. In some cases it's a good reason for failure (like the one you describe).
In other cases it's a bad reason for failure: it's also incredibly expensive to prove your drug works even if it does work for a lot of people.
That's bad! It'd be better if it were cheaper.
Actually counterintuitively, due to a weird drug approval and payor reimbursement policy arbitrage, pharma companies are highly incentivized to produce drugs for tiny populations.
One of my hobby horses is railing against this specific dynamic.
In other cases it's a bad reason for failure: it's also incredibly expensive to prove your drug works even if it does work for a lot of people.
That's bad! It'd be better if it were cheaper.
Actually counterintuitively, due to a weird drug approval and payor reimbursement policy arbitrage, pharma companies are highly incentivized to produce drugs for tiny populations.
One of my hobby horses is railing against this specific dynamic.